

David E Neal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5283346/publications.pdf>

Version: 2024-02-01

377
papers

31,808
citations

4942

84
h-index

5806

161
g-index

396
all docs

396
docs citations

396
times ranked

35910
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 755-761.	2.0	14
2	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	9.4	264
3	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 532-541.	2.0	16
4	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , 2021, 12, 1236.	5.8	40
5	KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. <i>Scientific Reports</i> , 2021, 11, 9264.	1.6	5
6	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. <i>European Urology Oncology</i> , 2021, 4, 570-579.	2.6	38
7	A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections. <i>World Journal of Urology</i> , 2021, , 1.	1.2	15
8	Men's experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study. <i>Cancer Causes and Control</i> , 2021, 32, 261-269.	0.8	8
9	The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. <i>BJU International</i> , 2020, 125, 506-514.	1.3	32
10	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. <i>European Urology</i> , 2020, 77, 320-330.	0.9	107
11	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. <i>British Journal of Cancer</i> , 2020, 123, 1063-1070.	2.9	15
12	Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. <i>BMJ Open</i> , 2020, 10, e036024.	0.8	7
13	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. <i>Cancers</i> , 2020, 12, 3254.	1.7	16
14	Independence of HIF1a and androgen signaling pathways in prostate cancer. <i>BMC Cancer</i> , 2020, 20, 469.	1.1	25
15	The effect of sample size on polygenic hazard models for prostate cancer. <i>European Journal of Human Genetics</i> , 2020, 28, 1467-1475.	1.4	14
16	Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. <i>Cancer Causes and Control</i> , 2020, 31, 431-449.	0.8	53
17	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1731-1738.	1.1	27
18	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-176.	1.3	22

#	ARTICLE	IF	CITATIONS
19	Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study. <i>Journal of Clinical Epidemiology</i> , 2019, 113, 200-213.	2.4	6
20	The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGFâ€I, IGFâ€II, IGFBPâ€1, IGFBPâ€2 and IGFBPâ€3 in a pooled analysis of 16,024 men from 22 studies. <i>International Journal of Cancer</i> , 2019, 145, 3244-3256.	2.3	14
21	Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. <i>European Urology</i> , 2019, 76, 329-337.	0.9	48
22	Effect of green tea and lycopene on the insulin-like growth factor system: the ProDiet randomized controlled trial. <i>European Journal of Cancer Prevention</i> , 2019, 28, 569-575.	0.6	7
23	Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2019, 48, 1416-1424.	0.9	51
24	A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk. <i>Cancer Research</i> , 2019, 79, 274-285.	0.4	25
25	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 208-216.	1.1	21
26	A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. <i>Oncogene</i> , 2019, 38, 1136-1150.	2.6	15
27	Identification of potential therapeutic targets in prostate cancer through a crossâ€species approach. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	46
28	Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 883.	3.8	296
29	Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. <i>Cancer Epidemiology</i> , 2018, 52, 99-105.	0.8	8
30	Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis. <i>Journal of Urology</i> , 2018, 199, 1470-1474.	0.2	11
31	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nature Genetics</i> , 2018, 50, 682-692.	9.4	182
32	Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer. <i>Cancer Causes and Control</i> , 2018, 29, 383-388.	0.8	15
33	Supporting prostate cancer survivors in primary care: Findings from a pilot trial of a nurse-led psycho-educational intervention (PROSPECTIV). <i>European Journal of Oncology Nursing</i> , 2018, 32, 73-81.	0.9	17
34	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 35-46.	2.4	16
35	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. <i>BMJ: British Medical Journal</i> , 2018, 360, j5757.	2.4	153
36	DESNT: A Poor Prognosis Category of Human Prostate Cancer. <i>European Urology Focus</i> , 2018, 4, 842-850.	1.6	30

#	ARTICLE	IF	CITATIONS
37	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. <i>Nature Communications</i> , 2018, 9, 4616.	5.8	43
38	ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer. <i>Cancer Prevention Research</i> , 2018, 11, 687-696.	0.7	32
39	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936.	9.4	652
40	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018, 9, 2256.	5.8	88
41	Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer. <i>International Journal of Cancer</i> , 2017, 140, 1881-1887.	2.3	16
42	Asporin is a stromally expressed marker associated with prostate cancer progression. <i>British Journal of Cancer</i> , 2017, 116, 775-784.	2.9	44
43	Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. <i>European Urology</i> , 2017, 72, 509-518.	0.9	26
44	Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. <i>Nature Communications</i> , 2017, 8, 374.	5.8	180
45	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. <i>British Journal of Cancer</i> , 2017, 117, 734-743.	2.9	7
46	Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial. <i>Cancer Causes and Control</i> , 2017, 28, 877-888.	0.8	2
47	Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. <i>International Journal of Cancer</i> , 2017, 140, 322-328.	2.3	17
48	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , 2017, 72, 22-31.	0.9	37
49	Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above. <i>Journal of Urology</i> , 2017, 197, 607-613.	0.2	18
50	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. <i>European Urology</i> , 2017, 71, 381-388.	0.9	41
51	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. <i>International Journal of Cancer</i> , 2017, 140, 75-85.	2.3	28
52	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. <i>PLoS Genetics</i> , 2017, 13, e1007001.	1.5	34
53	Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study. <i>BMJ Open</i> , 2017, 7, e017729.	0.8	27
54	Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a <sc>UK</sc> regional tertiary referral centre. <i>BJU International</i> , 2016, 118, 779-784.	1.3	14

#	ARTICLE	IF	CITATIONS
55	Prostate-specific antigen patterns in <scp>US</scp> and European populations: comparison of six diverse cohorts. <i>BJU International</i> , 2016, 118, 911-918.	1.3	5
56	<i>PALB2</i>,<i>CHEK2</i>and<i>ATM</i>rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	1.5	174
57	Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). <i>BMJ Open</i> , 2016, 6, e011063.	0.8	23
58	Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy. <i>Metabolomics</i> , 2016, 12, 120.	1.4	31
59	Circulating Folate and Vitamin B12 and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls. <i>European Urology</i> , 2016, 70, 941-951.	0.9	46
60	Kinase joins the chaperone club: Androgen-regulated kinome reveals choline kinase alpha as a potential drug target in prostate cancer. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1140262.	0.3	4
61	The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. <i>Oncologist</i> , 2016, 21, 716-722.	1.9	27
62	Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. <i>International Journal of Cancer</i> , 2016, 139, 1520-1533.	2.3	26
63	Blood lipids and prostate cancer: a Mendelian randomization analysis. <i>Cancer Medicine</i> , 2016, 5, 1125-1136.	1.3	68
64	Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up. <i>BJU International</i> , 2016, 117, E10-9.	1.3	120
65	Whole blood mRNA in prostate cancer reveals a four-gene androgen regulated panel. <i>Endocrine-Related Cancer</i> , 2016, 23, 797-812.	1.6	12
66	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1415-1424.	13.9	2,101
67	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1425-1437.	13.9	962
68	Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. <i>BJU International</i> , 2016, 118, 869-879.	1.3	52
69	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	7.7	157
70	Investigating the prostate specific antigen, body mass index and age relationship: is an age-adjusted BMI-adjusted PSA model clinically useful?. <i>Cancer Causes and Control</i> , 2016, 27, 1465-1474.	0.8	17
71	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. <i>Nature Communications</i> , 2016, 7, 10979.	5.8	50
72	Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee. <i>British Journal of Cancer</i> , 2016, 115, 90-94.	2.9	38

#	ARTICLE	IF	CITATIONS
73	Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial. <i>Trials</i> , 2016, 17, 497.	0.7	5
74	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. <i>BMC Medicine</i> , 2016, 14, 66.	2.3	42
75	Circulating Tumor Cell Count as an Indicator of Treatment Benefit in Advanced Prostate Cancer. <i>European Urology</i> , 2016, 70, 993-994.	0.9	4
76	Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes. <i>Statistical Methods in Medical Research</i> , 2016, 25, 1875-1891.	0.7	7
77	Misclassification of outcome in case-control studies: Methods for sensitivity analysis. <i>Statistical Methods in Medical Research</i> , 2016, 25, 2377-2393.	0.7	23
78	Insertion of an SVA-E retrotransposon into the <i>CASP8</i> gene is associated with protection against prostate cancer. <i>Human Molecular Genetics</i> , 2016, 25, 1008-1018.	1.4	22
79	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. <i>Cancer Research</i> , 2016, 76, 2288-2300.	0.4	117
80	Gene regulatory mechanisms underpinning prostate cancer susceptibility. <i>Nature Genetics</i> , 2016, 48, 387-397.	9.4	119
81	Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. <i>British Journal of Cancer</i> , 2016, 114, 945-952.	2.9	17
82	Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv371.	3.0	37
83	The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer. <i>European Urology</i> , 2016, 70, 214-218.	0.9	56
84	Validation of the Hospital Episode Statistics Outpatient Dataset in England. <i>Pharmacoeconomics</i> , 2016, 34, 161-168.	1.7	29
85	<i>HNF1B</i> variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. <i>Oncotarget</i> , 2016, 7, 74734-74746.	0.8	38
86	A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population. <i>Oncotarget</i> , 2016, 7, 21393-21403.	0.8	18
87	Selective Targeting of the TPX2 Site of Importin β Using Fragment-Based Ligand Design. <i>ChemMedChem</i> , 2015, 10, 1232-1239.	1.6	11
88	Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial. <i>BMJ Open</i> , 2015, 5, e008953.	0.8	18
89	Prediction of individual genetic risk to prostate cancer using a polygenic score. <i>Prostate</i> , 2015, 75, 1467-1474.	1.2	54
90	Spatial genomic heterogeneity within localized, multifocal prostate cancer. <i>Nature Genetics</i> , 2015, 47, 736-745.	9.4	395

#	ARTICLE	IF	CITATIONS
91	Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. <i>Nature Communications</i> , 2015, 6, 6605.	5.8	312
92	Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: Opportunities for lifestyle modification. <i>International Journal of Cancer</i> , 2015, 137, 1509-1515.	2.3	25
93	Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case-control study. <i>Cancer Causes and Control</i> , 2015, 26, 205-218.	0.8	33
94	Incidence of needle-tract seeding following prostate biopsy for suspected cancer: a review of the literature. <i>BJU International</i> , 2015, 115, 698-704.	1.3	26
95	Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. <i>European Urology</i> , 2015, 67, 993-1005.	0.9	96
96	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. <i>Cancer Discovery</i> , 2015, 5, 368-379.	7.7	56
97	Salt-Inducible Kinase 2 Regulates Mitotic Progression and Transcription in Prostate Cancer. <i>Molecular Cancer Research</i> , 2015, 13, 620-635.	1.5	45
98	Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for) Tj ETQq0 0 0 rgBT10verlock810 Tf 50 4		
99	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1121-1129.	1.1	56
100	A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy. <i>Journal of Pathology</i> , 2015, 236, 517-530.	2.1	99
101	Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial. <i>BMC Health Services Research</i> , 2015, 15, 80.	0.9	16
102	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. <i>Genome Research</i> , 2015, 25, 814-824.	2.4	69
103	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. <i>Nature Genetics</i> , 2015, 47, 367-372.	9.4	380
104	HES5 silencing is an early and recurrent change in prostate tumourigenesis. <i>Endocrine-Related Cancer</i> , 2015, 22, 131-144.	1.6	10
105	Surgical margin length and location affect recurrence rates after robotic prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 109.e7-109.e13.	0.8	61
106	The evolutionary history of lethal metastatic prostate cancer. <i>Nature</i> , 2015, 520, 353-357.	13.7	1,185
107	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. <i>Cancer Causes and Control</i> , 2015, 26, 1603-1616.	0.8	77
108	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. <i>Human Molecular Genetics</i> , 2015, 24, 5589-5602.	1.4	67

#	ARTICLE	IF	CITATIONS
109	Gleason drift in the <sc>NIHR P</sc>rotec<sc>T</sc> study. <i>Histopathology</i> , 2015, 66, 438-446.	1.6	9
110	Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 1142-1157.	2.2	107
111	Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	146
112	Genome-Wide Association Study of Prostate Cancerâ€™Specific Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1796-1800.	1.1	27
113	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. <i>Genetics in Medicine</i> , 2015, 17, 789-795.	1.1	87
114	Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy. <i>PLoS ONE</i> , 2015, 10, e0136735.	1.1	6
115	Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer. <i>Oncotarget</i> , 2015, 6, 21675-21684.	0.8	23
116	Development, validation and evaluation of an instrument for active monitoring of men with clinically localised prostate cancer: systematic review, cohort studies and qualitative study. <i>Health Services and Delivery Research</i> , 2015, 3, 1-138.	1.4	4
117	Polymorphisms of an Innate Immune Gene, Toll-Like Receptor 4, and Aggressive Prostate Cancer Risk: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e110569.	1.1	24
118	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. <i>ELife</i> , 2014, 3, .	2.8	318
119	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2014, 15, 1521-1532.	5.1	291
120	Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer. <i>PLoS Genetics</i> , 2014, 10, e1004129.	1.5	34
121	PROSPECTIVâ€™a pilot trial of a nurse-led psychoeducational intervention delivered in primary care to prostate cancer survivors: study protocol for a randomised controlled trial: TableÂ1. <i>BMJ Open</i> , 2014, 4, e005186.	0.8	10
122	Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis. <i>BMJ Open</i> , 2014, 4, e004285.	0.8	33
123	Adherence to Dietary and Lifestyle Recommendations and Prostate Cancer Risk in the Prostate Testing for Cancer and Treatment (ProtecT) Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2066-2077.	1.1	33
124	HES6 drives a critical <sc>AR</sc> transcriptional programme to induce castrationâ€™resistant prostate cancer through activation of an <sc>E</sc>2<sc>F</sc>1â€™mediated cell cycle network. <i>EMBO Molecular Medicine</i> , 2014, 6, 651-661.	3.3	74
125	Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1109-1118.	5.1	205
126	The ETS family member GABPÎ± modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer. <i>Nucleic Acids Research</i> , 2014, 42, 6256-6269.	6.5	33

#	ARTICLE	IF	CITATIONS
127	Men's knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study. <i>BMC Cancer</i> , 2014, 14, 812.	1.1	15
128	Genetic Variation in Prostate-Specific Antigen-Detected Prostate Cancer and the Effect of Control Selection on Genetic Association Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1356-1365.	1.1	26
129	The transcriptional programme of the androgen receptor (<sc>AR</sc>) in prostate cancer. <i>BJU International</i> , 2014, 113, 358-366.	1.3	38
130	Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group. <i>World Journal of Urology</i> , 2014, 32, 185-191.	1.2	28
131	Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging. <i>Cancer Research</i> , 2014, 74, 896-907.	0.4	122
132	Regulation of the localisation and function of the oncogene LYRIC/AEG1 by ubiquitination at K486 and K491. <i>Molecular Oncology</i> , 2014, 8, 633-641.	2.1	5
133	Nuclear <sc>ARRB</sc> 1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. <i>EMBO Journal</i> , 2014, 33, 1365-1382.	3.5	57
134	Late Imaging with [¹¹ C]Acetate Improves Detection of Tumor Fatty Acid Synthesis with PET. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1144-1149.	2.8	24
135	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. <i>Science</i> , 2014, 345, 1251-1243.	6.0	348
136	Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment preferences. <i>Trials</i> , 2014, 15, 323.	0.7	50
137	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , 2014, 46, 1103-1109.	9.4	408
138	The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals. <i>BMC Family Practice</i> , 2014, 15, 81.	2.9	40
139	Key considerations for the experimental training and evaluation of cancer odour detection dogs: lessons learnt from a double-blind, controlled trial of prostate cancer detection. <i>BMC Urology</i> , 2014, 14, 22.	0.6	89
140	Design and preliminary recruitment results of the Cluster randomised trial of PSA testing for Prostate cancer (CAP). <i>British Journal of Cancer</i> , 2014, 110, 2829-2836.	2.9	26
141	A Multinational, Multi-institutional Study Comparing Positive Surgical Margin Rates Among 22 393 Open, Laparoscopic, and Robot-assisted Radical Prostatectomy Patients. <i>European Urology</i> , 2014, 66, 450-456.	0.9	116
142	Estrogen receptor beta in prostate cancer: friend or foe?. <i>Endocrine-Related Cancer</i> , 2014, 21, T219-T234.	1.6	85
143	Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells. <i>Oncotarget</i> , 2014, 5, 3785-3799.	0.8	17
144	Method for sampling tissue for research which preserves pathological data in radical prostatectomy. <i>Prostate</i> , 2013, 73, 194-202.	1.2	22

#	ARTICLE	IF	CITATIONS
145	Targeting the pro-survival side-effects of androgen-deprivation therapy in prostate cancer. <i>BJU International</i> , 2013, 111, 532-533.	1.3	2
146	Men with prostate cancer make positive dietary changes following diagnosis and treatment. <i>Cancer Causes and Control</i> , 2013, 24, 1119-1128.	0.8	36
147	Prostate Cancer UK: the Blue Skies Forum. <i>Trends in Urology & Men's Health</i> , 2013, 4, 39-43.	0.2	1
148	The Androgen Receptor Induces a Distinct Transcriptional Program in Castration-Resistant Prostate Cancer in Man. <i>Cancer Cell</i> , 2013, 23, 35-47.	7.7	354
149	Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis. <i>BJU International</i> , 2013, 111, 1148-1155.	1.3	9
150	Very Low PSA Concentrations and Deletions of the KLK3 Gene. <i>Clinical Chemistry</i> , 2013, 59, 234-244.	1.5	12
151	Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study. <i>Cancer Causes and Control</i> , 2013, 24, 39-45.	0.8	8
152	Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. <i>Cancer Causes and Control</i> , 2013, 24, 323-334.	0.8	30
153	Predictors of the use of orthotopic bladder reconstruction after radical cystectomy for bladder cancer: data from a pilot study of 1756 cases 2004-2011. <i>BJU International</i> , 2013, 111, 1061-1067.	1.3	4
154	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. <i>Nature Genetics</i> , 2013, 45, 385-391.	9.4	492
155	Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 635-643.	0.8	30
156	Downregulation of Androgen Receptor Transcription by Promoter G-Quadruplex Stabilization as a Potential Alternative Treatment for Castrate-Resistant Prostate Cancer. <i>Biochemistry</i> , 2013, 52, 1429-1436.	1.2	23
157	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. <i>Human Molecular Genetics</i> , 2013, 22, 408-415.	1.4	118
158	The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 126-139.	1.5	64
159	Androgen deprivation treatment in prostate cancer. <i>BMJ, The</i> , 2013, 346, e8555-e8555.	3.0	13
160	Global assessment of network inference algorithms based on available literature of gene/protein interactions. <i>Turkish Journal of Biology</i> , 2013, 37, 547-555.	2.1	14
161	Psychological Impact of Prostate Biopsy: Physical Symptoms, Anxiety, and Depression. <i>Journal of Clinical Oncology</i> , 2013, 31, 4235-4241.	0.8	81
162	A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. <i>Human Molecular Genetics</i> , 2013, 22, 5056-5064.	1.4	130

#	ARTICLE	IF	CITATIONS
163	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. <i>Human Molecular Genetics</i> , 2013, 22, 2520-2528.	1.4	100
164	Using Genetic Proxies for Lifecourse Sun Exposure to Assess the Causal Relationship of Sun Exposure with Circulating Vitamin D and Prostate Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 597-606.	1.1	22
165	Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring. <i>European Journal of Cancer Prevention</i> , 2013, 22, 121-125.	0.6	7
166	Alcohol consumption and PSA-detected prostate cancer risk: A case-control nested in the ProtecT study. <i>International Journal of Cancer</i> , 2013, 132, 2176-2185.	2.3	31
167	The role of 1.5 Tesla magnetic resonance imaging in staging prostate cancer. <i>ANZ Journal of Surgery</i> , 2013, 83, 234-238.	0.3	17
168	Role of the androgen receptor in prostate cancer. <i>Trends in Urology & Men's Health</i> , 2013, 4, 26-30.	0.2	0
169	The first national clinical audit of prostate cancer care. <i>BJU International</i> , 2013, 112, 883-884.	1.3	3
170	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. <i>EMBO Journal</i> , 2012, 31, 1617-1617.	3.5	2
171	Circulating Insulin-Like Growth Factors and IGF-Binding Proteins in PSA-Detected Prostate Cancer: The Large Case-Control Study ProtecT. <i>Cancer Research</i> , 2012, 72, 503-515.	0.4	50
172	Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. <i>BMJ: British Medical Journal</i> , 2012, 344, d7894-d7894.	2.4	211
173	Associations of Lifestyle Factors and Anthropometric Measures with Repeat PSA Levels During Active Surveillance/Monitoring. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1877-1885.	1.1	19
174	Genetic and functional analyses implicate the <i>NUDT11</i> , <i>HNF1B</i> , and <i>SLC22A3</i> genes in prostate cancer pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 11252-11257.	3.3	102
175	Evaluating Genetic Risk for Prostate Cancer among Japanese and Latinos. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 2048-2058.	1.1	51
176	A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. <i>Nature Genetics</i> , 2012, 44, 1326-1329.	9.4	178
177	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , 2012, 30, 181-187.	1.2	66
178	Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade. <i>Cancer Causes and Control</i> , 2012, 23, 1865-1873.	0.8	23
179	Predictors of Attendance for Prostate-Specific Antigen Screening Tests and Prostate Biopsy. <i>European Urology</i> , 2012, 62, 649-655.	0.9	22
180	RB1 Methylation by SMYD2 Enhances Cell Cycle Progression through an Increase of RB1 Phosphorylation. <i>Neoplasia</i> , 2012, 14, 476-IN8.	2.3	169

#	ARTICLE	IF	CITATIONS
181	The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G ₁ /S transition in cancer cells via transcriptional regulation of the HOXA1 gene. <i>International Journal of Cancer</i> , 2012, 131, E179-89.	2.3	85
182	Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. <i>International Journal of Cancer</i> , 2012, 131, 1187-1196.	2.3	63
183	Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the Prostate testing for cancer and Treatment study. <i>Cancer Causes and Control</i> , 2012, 23, 575-588.	0.8	20
184	A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom. <i>Cancer Causes and Control</i> , 2012, 23, 907-917.	0.8	32
185	Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. <i>World Journal of Urology</i> , 2012, 30, 149-155.	1.2	101
186	The role of surgery in high-risk localised prostate cancer. <i>BJU International</i> , 2012, 109, 648-658.	1.3	24
187	Detailed analysis of operating time learning curves in robotic prostatectomy by a novice surgeon. <i>BJU International</i> , 2012, 109, 1074-1080.	1.3	22
188	General application of the National Institute for Health and Clinical Excellence (NICE) guidance for active surveillance for men with prostate cancer is not appropriate in unscreened populations. <i>BJU International</i> , 2012, 110, 24-27.	1.3	10
189	Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. <i>Cancer Causes and Control</i> , 2012, 23, 347-354.	0.8	32
190	No Evidence for Infection of UK Prostate Cancer Patients with XMRV, BK Virus, <i>Trichomonas vaginalis</i> or Human Papilloma Viruses. <i>PLoS ONE</i> , 2012, 7, e34221.	1.1	22
191	Histone Lysine Methyltransferase Wolf-Hirschhorn Syndrome Candidate 1 Is Involved in Human Carcinogenesis through Regulation of the Wnt Pathway. <i>Neoplasia</i> , 2011, 13, 887-IN11.	2.3	92
192	Growing Teratoma Syndrome: A Case of Mistaken Identity. <i>British Journal of Medical and Surgical Urology</i> , 2011, 4, 272-275.	0.2	0
193	Differential C3NET reveals disease networks of direct physical interactions. <i>BMC Bioinformatics</i> , 2011, 12, 296.	1.2	35
194	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. <i>Nature Genetics</i> , 2011, 43, 1098-1103.	9.4	251
195	Enhanced Expression of EHMT2 Is Involved in the Proliferation of Cancer Cells through Negative Regulation of SIAH1. <i>Neoplasia</i> , 2011, 13, 676-IN10.	2.3	112
196	A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 628-636.	2.4	18
197	Exploring treatment preferences facilitated recruitment to randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 1127-1136.	2.4	93
198	First 500 cases of robotic-assisted laparoscopic radical prostatectomy from a single UK centre: learning curves of two surgeons. <i>BJU International</i> , 2011, 108, 739-747.	1.3	45

#	ARTICLE	IF	CITATIONS
199	Trends in the use of radiotherapy and radical surgery for patients with bladder urothelial cell carcinoma in East Anglia, 1995-2006. <i>BJU International</i> , 2011, 108, 1106-1114.	1.3	7
200	Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. <i>BJU International</i> , 2011, 108, 1402-1408.	1.3	63
201	Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK. <i>BJU International</i> , 2011, 108, 1409-1414.	1.3	6
202	Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study. <i>British Journal of Cancer</i> , 2011, 104, 875-881.	2.9	23
203	The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. <i>EMBO Journal</i> , 2011, 30, 2719-2733.	3.5	530
204	Infective complications after transrectal ultrasound-guided prostate biopsy following a new protocol for antibiotic prophylaxis aimed at reducing hospital-acquired infections. <i>BJU International</i> , 2011, 108, 1597-1602.	1.3	29
205	Identification of a novel prostate cancer susceptibility variant in the <i>KLK3</i> gene transcript. <i>Human Genetics</i> , 2011, 129, 687-694.	1.8	83
206	Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. <i>Molecular Cancer</i> , 2011, 10, 65.	7.9	97
207	Prostate cancer metabolite quantification relative to water in ^1H -MRSI in vivo at 3 Tesla. <i>Magnetic Resonance in Medicine</i> , 2011, 65, 914-919.	1.9	22
208	Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. <i>International Journal of Cancer</i> , 2011, 128, 574-586.	2.3	420
209	Association of diabetes mellitus with prostate cancer: Nested case-control study (Prostate testing) T_j ETQq1 1 0,784314 rgBT /Over	2.3	56
210	Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. <i>International Journal of Cancer</i> , 2011, 128, 562-573.	2.3	260
211	Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: Findings from a large, population-based, case-control study (the ProtecT study). <i>International Journal of Cancer</i> , 2011, 128, 1442-1448.	2.3	41
212	PSA-detected prostate cancer and the potential for dedifferentiation: estimating the proportion capable of progression. <i>International Journal of Cancer</i> , 2011, 128, 1462-1470.	2.3	14
213	Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence. <i>Cancer Epidemiology</i> , 2011, 35, 139-144.	0.8	4
214	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. <i>Nature Genetics</i> , 2011, 43, 785-791.	9.4	265
215	Genome-wide association study identifies new prostate cancer susceptibility loci. <i>Human Molecular Genetics</i> , 2011, 20, 3867-3875.	1.4	160
216	The Histone Demethylase JMJD2B Plays an Essential Role in Human Carcinogenesis through Positive Regulation of Cyclin-Dependent Kinase 6. <i>Cancer Prevention Research</i> , 2011, 4, 2051-2061.	0.7	62

#	ARTICLE	IF	CITATIONS
217	Randomised surgical trials need good surgical outcomes in the control arm. <i>BMJ: British Medical Journal</i> , 2011, 343, d7520-d7520.	2.4	1
218	Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1090-1098.	3.2	100
219	Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. <i>British Journal of Cancer</i> , 2011, 105, 931-937.	2.9	18
220	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. <i>EMBO Journal</i> , 2011, 30, 3019-3027.	3.5	247
221	Association between Prostinogen (KLK15) Genetic Variants and Prostate Cancer Risk and Aggressiveness in Australia and a Meta-Analysis of GWAS Data. <i>PLoS ONE</i> , 2011, 6, e26527.	1.1	14
222	Pre-malignant Disease in the Prostate. , 2011, , 467-491.		0
223	The Development of a Robotic Urology Program in the UK. , 2011, , 97-109.		0
224	The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers?. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 316-27.	0.4	9
225	Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. <i>Biochemical Journal</i> , 2010, 428, 439-450.	1.7	149
226	Where are we now with prostate cancer diagnosis?. <i>Trends in Urology & Men's Health</i> , 2010, 1, 18-20.	0.2	2
227	The relation between adiposity throughout the life course and variation in IGFs and IGFbps: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. <i>Cancer Causes and Control</i> , 2010, 21, 1829-1842.	0.8	26
228	Development of a New Method for Monitoring Prostate-Specific Antigen Changes in Men with Localised Prostate Cancer: A Comparison of Observational Cohorts. <i>European Urology</i> , 2010, 57, 446-452.	0.9	12
229	The potential value of microseminoprotein- β^2 as a prostate cancer biomarker and therapeutic target. <i>Prostate</i> , 2010, 70, 333-340.	1.2	55
230	Mutation analysis of the MSMB gene in familial prostate cancer. <i>British Journal of Cancer</i> , 2010, 102, 414-418.	2.9	19
231	Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. <i>British Journal of Cancer</i> , 2010, 102, 1335-1340.	2.9	77
232	ENHANCED RECOVERY: FROM PRINCIPLES TO PRACTICE IN UROLOGY. <i>BJU International</i> , 2010, 105, 1199-1201.	1.3	9
233	The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine. <i>PLoS ONE</i> , 2010, 5, e13363.	1.1	73
234	Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels. <i>Science Translational Medicine</i> , 2010, 2, 62ra92.	5.8	140

#	ARTICLE	IF	CITATIONS
235	Associations of Folate, Vitamin B12, Homocysteine, and Folate-Pathway Polymorphisms with Prostate-Specific Antigen Velocity in Men with Localized Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2833-2838.	1.1	20
236	The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group. <i>Clinical Cancer Research</i> , 2010, 16, 4374-4381.	3.2	86
237	Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: continuous survey. <i>BMJ: British Medical Journal</i> , 2010, 340, c1928-c1928.	2.4	49
238	RAS Pathways in Prostate Cancer - Mediators of Hormone Resistance?. <i>Current Cancer Drug Targets</i> , 2010, 10, 834-839.	0.8	17
239	Circulating Folate, Vitamin B12, Homocysteine, Vitamin B12 Transport Proteins, and Risk of Prostate Cancer: a Case-Control Study, Systematic Review, and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1632-1642.	1.1	142
240	Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. <i>Molecular Cancer</i> , 2010, 9, 59.	7.9	183
241	Tumor Necrosis Factor Receptor Expression and Signaling in Renal Cell Carcinoma. <i>American Journal of Pathology</i> , 2010, 177, 943-954.	1.9	58
242	PSA testing for prostate cancer improves survivalâ€”but can we do better?. <i>Lancet Oncology</i> , The, 2010, 11, 702-703.	5.1	15
243	Evaluation of Association of HNF1B Variants with Diverse Cancers: Collaborative Analysis of Data from 19 Genome-Wide Association Studies. <i>PLoS ONE</i> , 2010, 5, e10858.	1.1	28
244	Associations between an Obesity Related Genetic Variant (FTO rs9939609) and Prostate Cancer Risk. <i>PLoS ONE</i> , 2010, 5, e13485.	1.1	61
245	A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the Tj ETQq1 1 0784314 ngBT /Overl	2.0	16
246	PTGS2â€”899G>C and prostate cancer risk: a population-based nested caseâ€”control study (ProtecT) and a systematic review with meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2009, 12, 296-300.	2.0	16
247	Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. <i>British Journal of Cancer</i> , 2009, 100, 1198-1204.	2.9	58
248	A recurrent truncating germline mutation in the BRIP1/FANCI gene and susceptibility to prostate cancer. <i>British Journal of Cancer</i> , 2009, 100, 426-430.	2.9	57
249	Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale health services research. <i>Journal of Health Services Research and Policy</i> , 2009, 14, 77-81.	0.8	16
250	Stage Shift in Psa-detected Prostate Cancers â€” Effect Modification by Gleason Score. <i>Journal of Medical Screening</i> , 2009, 16, 98-101.	1.1	19
251	LYRIC/AEG-1 Is Targeted to Different Subcellular Compartments by Ubiquitinylation and Intrinsic Nuclear Localization Signals. <i>Clinical Cancer Research</i> , 2009, 15, 3003-3013.	3.2	75
252	Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2874-2881.	1.1	64

#	ARTICLE	IF	CITATIONS
253	Association of Folate-Pathway Gene Polymorphisms with the Risk of Prostate Cancer: a Population-Based Nested Case-Control Study, Systematic Review, and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2528-2539.	1.1	89
254	It's not just what you say, it's also how you say it: Opening the "black box"™ of informed consent appointments in randomised controlled trials. <i>Social Science and Medicine</i> , 2009, 68, 2018-2028.	1.8	154
255	Life course sun exposure and risk of prostate cancer: Population-based nested case-control study and meta-analysis. <i>International Journal of Cancer</i> , 2009, 125, 1414-1423.	2.3	49
256	Identification of new genetic risk factors for prostate cancer. <i>Asian Journal of Andrology</i> , 2009, 11, 49-55.	0.8	23
257	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. <i>Nature Genetics</i> , 2009, 41, 1116-1121.	9.4	389
258	Multiple loci on 8q24 associated with prostate cancer susceptibility. <i>Nature Genetics</i> , 2009, 41, 1058-1060.	9.4	273
259	Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study. <i>British Journal of Cancer</i> , 2009, 101, 390-394.	2.9	17
260	Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. <i>BJU International</i> , 2009, 104, 1592-1598.	1.3	69
261	Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?. <i>European Journal of Cancer</i> , 2009, 45, 2569-2573.	1.3	18
262	Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: A case-control study nested within the UK population-based ProtecT (Prostate testing for) Tj ETQq0 0 0 rgBIT.3 Overload 10 Tf 50		
263	Psychological distress and prostate specific antigen levels in men with and without prostate cancer. <i>Brain, Behavior, and Immunity</i> , 2009, 23, 1073-1078.	2.0	6
264	Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 29-36.	2.4	133
265	Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 67-73.	2.4	12
266	Clarification of NICE Guidance on Prostate Cancer. <i>British Journal of Medical and Surgical Urology</i> , 2009, 2, 219-223.	0.2	1
267	Cancer, Chemistry, and the Cell: Molecules that Interact with the Neurotensin Receptors. <i>ACS Chemical Biology</i> , 2009, 4, 503-525.	1.6	69
268	Screening for prostate cancer remains controversial. <i>Lancet, The</i> , 2009, 374, 1482-1483.	6.3	22
269	Treatment for PSA screen-detected prostate cancer: what are the options?. <i>Nature Reviews Urology</i> , 2009, 6, 132-134.	1.9	0
270	Pro-neural transcription factors as cancer markers. <i>BMC Medical Genomics</i> , 2008, 1, 17.	0.7	32

#	ARTICLE	IF	CITATIONS
271	Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. <i>Prostate</i> , 2008, 68, 661-674.	1.2	51
272	Alterations in β -catenin expression and localization in prostate cancer. <i>Prostate</i> , 2008, 68, 1196-1205.	1.2	67
273	Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over. <i>Modern Pathology</i> , 2008, 21, 54-59.	2.9	40
274	Multiple newly identified loci associated with prostate cancer susceptibility. <i>Nature Genetics</i> , 2008, 40, 316-321.	9.4	796
275	Reply to "Variation in KLK genes, prostate-specific antigen and risk of prostate cancer". <i>Nature Genetics</i> , 2008, 40, 1035-1036.	9.4	31
276	Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. <i>BJU International</i> , 2008, 101, 547-555.	1.3	53
277	Stage migration and pilot studies of reduced chemotherapy supported by positron-emission tomography findings suggest new combined strategies for stage 2 nonseminoma germ cell tumour. <i>BJU International</i> , 2008, 101, 570-574.	1.3	6
278	Is continent diversion using the Mitrofanoff principle a viable long-term option for adults requiring bladder replacement?. <i>BJU International</i> , 2008, 102, 236-240.	1.3	23
279	Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. <i>BJU International</i> , 2008, 102, 1400-1406.	1.3	41
280	Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?. <i>BJU International</i> , 2008, 102, 1629-1633.	1.3	10
281	Decision-Making about PSA Testing and Prostate Biopsies: A Qualitative Study Embedded in a Primary Care Randomised Trial. <i>European Urology</i> , 2008, 53, 1186-1193.	0.9	41
282	Contribution of a Single Repeat PSA Test to Prostate Cancer Risk Assessment: Experience from the ProtecT Study. <i>European Urology</i> , 2008, 53, 777-784.	0.9	19
283	The role of the Postgraduate Medical Education and Training Board (PMETB). <i>Surgery</i> , 2008, 26, 403-407.	0.1	1
284	Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. <i>Lancet Oncology</i> , The, 2008, 9, 445-452.	5.1	231
285	Can We Accurately Identify Men With Low Risk Prostate Cancer?. <i>Journal of Urology</i> , 2008, 180, 1217-1218.	0.2	8
286	Low risk research using routinely collected identifiable health information without informed consent: encounters with the Patient Information Advisory Group. <i>Journal of Medical Ethics</i> , 2008, 34, 37-40.	1.0	26
287	Structural basis for the nuclear import of the human androgen receptor. <i>Journal of Cell Science</i> , 2008, 121, 957-968.	1.2	193
288	AURKA overexpression accompanies dysregulation of DNA-damage response genes in invasive urothelial cell carcinoma. <i>Cell Cycle</i> , 2008, 7, 3525-3533.	1.3	13

#	ARTICLE	IF	CITATIONS
289	Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2052-2061.	1.1	148
290	Height and Prostate Cancer Risk: A Large Nested Case-Control Study (Protect) and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2325-2336.	1.1	83
291	Multiple Loci With Different Cancer Specificities Within the 8q24 Gene Desert. <i>Journal of the National Cancer Institute</i> , 2008, 100, 962-966.	3.0	306
292	High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers Identifies <i>Mouse Double Minute 4</i> (<i>MDM4</i>) as an Amplification Target Exclusive of <i>MDM2</i> and <i>TP53</i> . <i>Clinical Cancer Research</i> , 2008, 14, 2527-2534.	3.2	37
293	Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2007, 335, 1139.	2.4	18
294	RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. <i>Prostate</i> , 2007, 67, 638-644.	1.2	36
295	A role for neurotensin in bicalutamide resistant prostate cancer cells. <i>Prostate</i> , 2007, 67, 190-202.	1.2	30
296	Labeling and identification of LNCaP cell surface proteins: A pilot study. <i>Prostate</i> , 2007, 67, 943-954.	1.2	17
297	New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. <i>EMBO Reports</i> , 2007, 8, 871-878.	2.0	240
298	Oral ciprofloxacin or trimethoprim reduces bacteriuria after flexible cystoscopy. <i>BJU International</i> , 2007, 100, 826-829.	1.3	56
299	Missing channels in two-colour microarray experiments: Combining single-channel and two-channel data. <i>BMC Bioinformatics</i> , 2007, 8, 26.	1.2	4
300	A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. <i>BMC Genomics</i> , 2007, 8, 84.	1.2	39
301	Reducing Warm Ischaemia Time During Laparoscopic Partial Nephrectomy: A Prospective Comparison of Two Renal Closure Techniques. <i>European Urology</i> , 2007, 52, 1164-1169.	0.9	127
302	Non-invasive diagnosis. , 2007, , 39-49.		1
303	Continuing Controversy Over Monitoring Men With Localized Prostate Cancer: A Systematic Review of Programs in the Prostate Specific Antigen Era. <i>Journal of Urology</i> , 2006, 176, 439-449.	0.2	45
304	A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study). <i>Contemporary Clinical Trials</i> , 2006, 27, 413-419.	0.8	22
305	ESTABLISHING A ROBOTIC PROSTATECTOMY PROGRAMME: THE IMPACT OF MENTORING USING A STRUCTURED APPROACH. <i>BJU International</i> , 2006, 97, 1143-1144.	1.3	17
306	Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. <i>BJU International</i> , 2006, 98, 777-782.	1.3	40

#	ARTICLE	IF	CITATIONS
307	Fournier's gangrene. <i>Nature Reviews Urology</i> , 2006, 3, 54-57.	1.4	10
308	A model of the natural history of screen-detected prostate cancer. <i>British Journal of Cancer</i> , 2006, 95, 1122-1123.	2.9	4
309	Molecular medicine and its impact on practice. <i>Nature Reviews Urology</i> , 2005, 2, 59-59.	1.4	0
310	Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. <i>Nucleic Acids Research</i> , 2005, 33, 13-26.	6.5	158
311	Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors. <i>Journal of Cell Biology</i> , 2005, 170, 191-200.	2.3	66
312	Can a point-of-care proteomic assay increase the accuracy of cystoscopy?. <i>Nature Reviews Urology</i> , 2005, 2, 320-321.	1.4	0
313	Do Height-Related Variations in Insulin-Like Growth Factors Underlie the Associations of Stature with Adult Chronic Disease?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 213-218.	1.8	52
314	Serum Insulin-Like Growth Factor-I Is Positively Associated with Serum Prostate-Specific Antigen in Middle-Aged Men without Evidence of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 163-165.	1.1	19
315	CD133, a novel marker for human prostatic epithelial stem cells. <i>Journal of Cell Science</i> , 2004, 117, 3539-3545.	1.2	714
316	Putative involvement of the histone acetyltransferase Tip60 in ribosomal gene transcription. <i>Nucleic Acids Research</i> , 2004, 32, 1654-1665.	6.5	43
317	Control of Human PIRH2 Protein Stability. <i>Journal of Biological Chemistry</i> , 2004, 279, 11696-11704.	1.6	56
318	Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 4874-4884.	3.2	78
319	Mucus production after transposition of intestinal segments into the urinary tract. <i>World Journal of Urology</i> , 2004, 22, 178-185.	1.2	22
320	Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer. <i>Prostate</i> , 2004, 59, 177-189.	1.2	475
321	Screen-detected prostate cancer and the insulin-like growth factor axis: Results of a population-based case-control study. <i>International Journal of Cancer</i> , 2004, 108, 887-892.	2.3	51
322	Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. <i>Urology</i> , 2004, 64, 317-322.	0.5	12
323	Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. <i>Contemporary Clinical Trials</i> , 2003, 24, 272-282.	2.0	118
324	Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion. <i>BJU International</i> , 2003, 91, 331-336.	1.3	44

#	ARTICLE	IF	CITATIONS
325	Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. <i>Oncogene</i> , 2003, 22, 2466-2477.	2.6	206
326	Screening for prostate cancer. <i>Lancet, The</i> , 2003, 361, 1122-1128.	6.3	227
327	Who can best recruit to randomized trials?. <i>Journal of Clinical Epidemiology</i> , 2003, 56, 605-609.	2.4	68
328	Including a 'no active intervention' arm in surgical trials is possible: evidence from the CLasP randomised trial. <i>Journal of Health Services Research and Policy</i> , 2003, 8, 209-214.	0.8	4
329	Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-1 and IGFBP-3 in healthy middle-aged men. <i>British Journal of Cancer</i> , 2003, 88, 1682-1686.	2.9	123
330	The Scaffolding Protein RACK1 Interacts with Androgen Receptor and Promotes Cross-talk through a Protein Kinase C Signaling Pathway. <i>Journal of Biological Chemistry</i> , 2003, 278, 46087-46093.	1.6	51
331	Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study * Commentary: presenting unbiased information to patients can be difficult. <i>BMJ: British Medical Journal</i> , 2002, 325, 766-770.	2.4	461
332	Evaluation of Dendritic Cell Immunogenicity After Activation and Chemical Fixation: A Mixed Lymphocyte Reaction Model. <i>Journal of Immunotherapy</i> , 2002, 25, 152-161.	1.2	2
333	Tip60 and Histone Deacetylase 1 Regulate Androgen Receptor Activity through Changes to the Acetylation Status of the Receptor. <i>Journal of Biological Chemistry</i> , 2002, 277, 25904-25913.	1.6	268
334	Transfection of S100A4 Produces Metastatic Variants of an Orthotopic Model of Bladder Cancer. <i>American Journal of Pathology</i> , 2002, 160, 693-700.	1.9	34
335	Transurethral Prostate Resection, Noncontact Laser Therapy or Conservative Management in Men With Symptoms of Benign Prostatic Enlargement? An Economic Evaluation. <i>Journal of Urology</i> , 2002, 168, 2476-2482.	0.2	16
336	Adhesion of lymphocytes to bladder cancer cells: the role of the $\alpha 7 \beta 1$ integrin. <i>Cancer Immunology, Immunotherapy</i> , 2002, 51, 483-491.	2.0	18
337	Vitamin B12 malabsorption following bladder reconstruction or diversion with bowel segments. <i>ANZ Journal of Surgery</i> , 2002, 72, 479-482.	0.3	21
338	Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer. <i>Journal of Pathology</i> , 2002, 196, 292-299.	2.1	104
339	Regulation of FGF8 expression by the androgen receptor in human prostate cancer. <i>Oncogene</i> , 2002, 21, 5069-5080.	2.6	74
340	Screening for prostate cancer in the UK. <i>BMJ: British Medical Journal</i> , 2001, 323, 763-764.	2.4	31
341	Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells. <i>Oncogene</i> , 2001, 20, 5359-5365.	2.6	40
342	Tip60 Is a Co-activator Specific for Class I Nuclear Hormone Receptors. <i>Journal of Biological Chemistry</i> , 2001, 276, 46841-46848.	1.6	83

#	ARTICLE	IF	CITATIONS
343	Identification and isolation of human prostate epithelial stem cells based on $\alpha_1\beta_1$ -integrin expression. <i>Journal of Cell Science</i> , 2001, 114, 3865-3872.	1.2	316
344	Androgen Receptor Nuclear Translocation Is Facilitated by the f-Actin Cross-Linking Protein Filamin. <i>Molecular Endocrinology</i> , 2000, 14, 1618-1626.	3.7	133
345	Prostate cancer: to screen or not to screen?. <i>Lancet Oncology</i> , The, 2000, 1, 17-24.	5.1	65
346	A RANDOMIZED TRIAL COMPARING TRANSURETHRAL RESECTION OF THE PROSTATE, LASER THERAPY AND CONSERVATIVE TREATMENT OF MEN WITH SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC ENLARGEMENT: THE CLasP STUDY. <i>Journal of Urology</i> , 2000, 164, 65-70.	0.2	81
347	NEURAL NETWORK ANALYSIS OF CLINICOPATHOLOGICAL AND MOLECULAR MARKERS IN BLADDER CANCER. <i>Journal of Urology</i> , 2000, 163, 630-633.	0.2	56
348	NEURAL NETWORK ANALYSIS OF CLINICOPATHOLOGICAL AND MOLECULAR MARKERS IN BLADDER CANCER. <i>Journal of Urology</i> , 2000, , 630.	0.2	1
349	Tip60 Is a Nuclear Hormone Receptor Coactivator. <i>Journal of Biological Chemistry</i> , 1999, 274, 17599-17604.	1.6	225
350	FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. <i>Oncogene</i> , 1999, 18, 2755-2761.	2.6	133
351	aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. , 1999, 189, 564-569.		54
352	Ryanodine receptors in human bladder smooth muscle. <i>Experimental Physiology</i> , 1999, 84, 41-46.	0.9	18
353	The immunohistochemical detection of cripto-1 in benign and malignant human bladder. , 1998, 185, 108-111.		10
354	Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. , 1998, 37, 149-160.		135
355	Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. , 1998, 37, 223-229.		75
356	Screening for prostate cancer. <i>Annals of Oncology</i> , 1998, 9, 1289-1292.	0.6	10
357	Neuromodulation in bladder dysfunction. <i>Current Opinion in Obstetrics and Gynecology</i> , 1998, 10, 395-399.	0.9	10
358	Fibroblast Growth Factor Receptor (FGFR). <i>Expert Opinion on Therapeutic Targets</i> , 1997, 1, 173-175.	1.0	0
359	Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction. <i>Urology</i> , 1997, 50, 55-61.	0.5	20
360	Androgen regulation of ornithine decarboxylase in human prostatic cells identified using differential display. <i>FEBS Letters</i> , 1997, 405, 328-332.	1.3	30

#	ARTICLE	IF	CITATIONS
361	Keratinocyte growth factor expression in hormone insensitive prostate cancer. <i>Oncogene</i> , 1997, 15, 1115-1120.	2.6	83
362	Basic science aspects of prostate cancer. <i>Seminars in Cancer Biology</i> , 1997, 8, 21-27.	4.3	34
363	The molecular pathology of urological malignancies. , 1997, 183, 380-387.		29
364	Effects of a new 5 α reductase inhibitor (epristeride) on human prostate cell cultures. , 1997, 32, 259-265.		9
365	Transcutaneous Electrical Nerve Stimulation and Temporary S3 Neuromodulation in Idiopathic Detrusor Instability. <i>Journal of Urology</i> , 1996, 155, 2005-2011.	0.2	67
366	Conventional Urodynamics and Ambulatory Monitoring in the Definition and Management of Bladder Outflow Obstruction. <i>Journal of Urology</i> , 1996, 155, 506-511.	0.2	65
367	Surface Localization of Sacral Foramina for Neuromodulation of Bladder Function. <i>European Urology</i> , 1996, 29, 90-98.	0.9	29
368	The morbidity of transurethral resection of the prostate. <i>Current Opinion in Urology</i> , 1996, 6, 147-150.	0.9	6
369	Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer. <i>Nature Medicine</i> , 1996, 2, 912-917.	15.2	255
370	High level expression of the multidrug resistance (MDRI) gene in the normal bladder urothelium: a potential involvement in protection against carcinogens?. <i>Carcinogenesis</i> , 1996, 17, 601-604.	1.3	22
371	Transrectal ultrasound guided needle electromyography of the urethral sphincter in males. <i>Neurourology and Urodynamics</i> , 1995, 14, 359-363.	0.8	4
372	Original Articles: Bladder Cancer: Long-Term Outcome Related to Epidermal Growth Factor Receptor Status in Bladder Cancer. <i>Journal of Urology</i> , 1995, 153, 919-925.	0.2	147
373	Detrusor contraction strength in men undergoing prostatectomy. <i>Neurourology and Urodynamics</i> , 1993, 12, 109-121.	0.8	14
374	Clean intermittent self catheterization. <i>International Urogynecology Journal</i> , 1993, 4, 250-251.	0.7	0
375	Epidermal Growth Factor Receptor and Bladder Cancer: A Review. <i>Urologia Internationalis</i> , 1992, 48, 365-371.	0.6	72
376	The Outcome of Prostatectomy on Chronic Retention of Urine. <i>Journal of Urology</i> , 1991, 146, 1029-1033.	0.2	10
377	The epidermal growth factor receptor and the prognosis of bladder cancer. <i>Cancer</i> , 1990, 65, 1619-1625.	2.0	336